Maxim Group Maintains a Hold Rating on Vertex Pharmaceuticals (VRTX)
Maxim Group analyst Jason McCarthy maintained a Hold rating on Vertex Pharmaceuticals (VRTX) yesterday. The company’s shares closed last Thursday at $271.46.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 28.7% and a 50.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $312.44.
See today’s analyst top recommended stocks >>
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.52 billion and net profit of $837 million. In comparison, last year the company earned revenue of $941 million and had a net profit of $267 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Read More on VRTX: